Posters and Abstracts – Seda https://www.sedapds.com Thu, 17 Jul 2025 13:08:12 +0000 en-GB hourly 1 Long-Acting Injectable Dose Prediction: Where Are We Really? https://www.sedapds.com/publication/long-acting-injectable-dose-prediction-where-are-we-really/?utm_source=rss&utm_medium=rss&utm_campaign=long-acting-injectable-dose-prediction-where-are-we-really Thu, 17 Jul 2025 13:08:12 +0000 https://www.sedapds.com/?post_type=publication&p=2453 The post Long-Acting Injectable Dose Prediction: Where Are We Really? appeared first on Seda.

]]> The post Long-Acting Injectable Dose Prediction: Where Are We Really? appeared first on Seda.

]]> Translational PK/PD Modelling of MEK inhibitors: Trametinib, Cobimetinib and Binimetinib https://www.sedapds.com/publication/translational-pk-pd-modelling-of-mek-inhibitors-trametinib-cobimetinib-and-binimetinib/?utm_source=rss&utm_medium=rss&utm_campaign=translational-pk-pd-modelling-of-mek-inhibitors-trametinib-cobimetinib-and-binimetinib Thu, 08 May 2025 10:27:34 +0000 https://www.sedapds.com/?post_type=publication&p=2414 The post Translational PK/PD Modelling of MEK inhibitors: Trametinib, Cobimetinib and Binimetinib appeared first on Seda.

]]> The post Translational PK/PD Modelling of MEK inhibitors: Trametinib, Cobimetinib and Binimetinib appeared first on Seda.

]]> Harnessing GitLab, R and LaTeX to perform bespoke and robust non-compartmental analysis for patient SAD and MAD studies https://www.sedapds.com/publication/harnessing-gitlab-r-and-latex-to-perform-bespoke-and-robust-non-compartmental-analysis-for-patient-sad-and-mad-studies/?utm_source=rss&utm_medium=rss&utm_campaign=harnessing-gitlab-r-and-latex-to-perform-bespoke-and-robust-non-compartmental-analysis-for-patient-sad-and-mad-studies Wed, 27 Nov 2024 18:04:23 +0000 https://www.sedapds.com/?post_type=publication&p=2310 The post Harnessing GitLab, R and LaTeX to perform bespoke and robust non-compartmental analysis for patient SAD and MAD studies appeared first on Seda.

]]> The post Harnessing GitLab, R and LaTeX to perform bespoke and robust non-compartmental analysis for patient SAD and MAD studies appeared first on Seda.

]]> Investigating the influence of manufacturing process of lipid-based formulations on intracellular delivery of siRNA https://www.sedapds.com/publication/investigating-the-influence-of-manufacturing-process-of-lipid-based-formulations-on-intracellular-delivery-of-sirna/?utm_source=rss&utm_medium=rss&utm_campaign=investigating-the-influence-of-manufacturing-process-of-lipid-based-formulations-on-intracellular-delivery-of-sirna Thu, 20 Jun 2024 15:10:23 +0000 https://www.sedapds.com/?post_type=publication&p=2223 The post Investigating the influence of manufacturing process of lipid-based formulations on intracellular delivery of siRNA appeared first on Seda.

]]> The post Investigating the influence of manufacturing process of lipid-based formulations on intracellular delivery of siRNA appeared first on Seda.

]]> Model Informed-Development of Amorphous Systems (MI-DAS) – an in-silico polymer selection tool for ASD development https://www.sedapds.com/publication/model-informed-development-of-amorphous-systems-mi-das-an-in-silico-polymer-selection-tool-for-asd-development/?utm_source=rss&utm_medium=rss&utm_campaign=model-informed-development-of-amorphous-systems-mi-das-an-in-silico-polymer-selection-tool-for-asd-development Fri, 05 Jan 2024 11:19:47 +0000 https://www.sedapds.com/?post_type=publication&p=1989 The post Model Informed-Development of Amorphous Systems (MI-DAS) – an in-silico polymer selection tool for ASD development appeared first on Seda.

]]> The post Model Informed-Development of Amorphous Systems (MI-DAS) – an in-silico polymer selection tool for ASD development appeared first on Seda.

]]> Setting up success in the clinic through semi-mechanistic translational modelling https://www.sedapds.com/publication/setting-up-success-in-the-clinic-through-semi-mechanistic-translational-modelling/?utm_source=rss&utm_medium=rss&utm_campaign=setting-up-success-in-the-clinic-through-semi-mechanistic-translational-modelling Wed, 22 Mar 2023 12:38:14 +0000 https://www.sedapds.com/?post_type=publication&p=1827 The post Setting up success in the clinic through semi-mechanistic translational modelling appeared first on Seda.

]]> The post Setting up success in the clinic through semi-mechanistic translational modelling appeared first on Seda.

]]> Population PK modelling as an alternative route to bioequivalence https://www.sedapds.com/publication/population-pk-modelling-as-an-alternative-route-to-bioequivanlence/?utm_source=rss&utm_medium=rss&utm_campaign=population-pk-modelling-as-an-alternative-route-to-bioequivanlence Wed, 24 Aug 2022 10:38:54 +0000 https://www.sedapds.com/?post_type=publication&p=1513 The post Population PK modelling as an alternative route to bioequivalence appeared first on Seda.

]]> The post Population PK modelling as an alternative route to bioequivalence appeared first on Seda.

]]> Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections https://www.sedapds.com/publication/development-of-a-methodology-to-enable-non-linear-in-vitro-in-vivo-correlation-for-complex-long-acting-injections-2/?utm_source=rss&utm_medium=rss&utm_campaign=development-of-a-methodology-to-enable-non-linear-in-vitro-in-vivo-correlation-for-complex-long-acting-injections-2 Mon, 09 May 2022 07:36:48 +0000 https://www.sedapds.com/?post_type=publication&p=1329 The post Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections appeared first on Seda.

]]> The post Development of a methodology to enable non-linear in vitro-in vivo correlation for complex long-acting injections appeared first on Seda.

]]> First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies https://www.sedapds.com/publication/first-in-human-modular-study-of-samuraciclib-ct7001-a-first-in-class-oral-selective-inhibitor-of-cdk7-in-patients-with-advanced-solid-malignancies/?utm_source=rss&utm_medium=rss&utm_campaign=first-in-human-modular-study-of-samuraciclib-ct7001-a-first-in-class-oral-selective-inhibitor-of-cdk7-in-patients-with-advanced-solid-malignancies Thu, 11 Nov 2021 10:30:44 +0000 https://www.sedapds.com/?post_type=publication&p=1096 The post First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies appeared first on Seda.

]]> The post First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies appeared first on Seda.

]]> Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) https://www.sedapds.com/publication/study-of-samuraciclib-ct7001-a-first-in-class-oral-selective-inhibitor-of-cdk7-in-combination-with-fulvestrant-in-patients-with-advanced-hormone-receptor-positive-her2-negative-breast-cancer-hr/?utm_source=rss&utm_medium=rss&utm_campaign=study-of-samuraciclib-ct7001-a-first-in-class-oral-selective-inhibitor-of-cdk7-in-combination-with-fulvestrant-in-patients-with-advanced-hormone-receptor-positive-her2-negative-breast-cancer-hr Thu, 11 Nov 2021 10:30:23 +0000 https://www.sedapds.com/?post_type=publication&p=1095 The post Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) appeared first on Seda.

]]> The post Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) appeared first on Seda.

]]>